APUS — Apimeds Pharmaceuticals US Cashflow Statement
0.000.00%
Last trade - 00:00- $19.89m
- $20.51m
Annual cashflow statement for Apimeds Pharmaceuticals US, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS/A | PROSPECTUS/A | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -1.03 | -0.669 | -0.778 | -1.39 |
| Non-Cash Items | 0.2 | 0.223 | 0.108 | 0.08 |
| Other Non-Cash Items | ||||
| Changes in Working Capital | 0.003 | -0.002 | 0.042 | 0.577 |
| Change in Prepaid Expenses | ||||
| Change in Accrued Expenses | ||||
| Change in Payable / Accrued Expenses | ||||
| Cash from Operating Activities | -0.823 | -0.448 | -0.628 | -0.734 |
| Other Investing Cash Flow Items | 0 | 0 | 0 | — |
| Other Investing Cash Flow | ||||
| Cash from Investing Activities | 0 | 0 | 0 | — |
| Financing Cash Flow Items | 0 | 0.023 | -0.023 | 0.076 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 0.4 | 0.283 | 1.03 | 0.327 |
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | -0.423 | -0.165 | 0.404 | -0.407 |